Department of Medicine, DIMED, General Pathology,Cytopathology Unit, University of Padova, Padova, Italy.
Front Biosci (Landmark Ed). 2014 Jun 1;19(7):1088-104. doi: 10.2741/4269.
In recent years, DNA-arrays, gene expression profiling and next-generation sequencing have elucidated the high complexity of genomic alterations occurring in lymphoid malignancies. These studies have also contributed to the identification of new diagnostic and prognostic biomarkers, which may represent possible targets for new therapeutic approaches. Such recent advances have significantly expanded the application of molecular tests to routine diagnostic hematopathology. It is thus conceivable that next-generation assays will soon flank traditional clonality tests and chromosomal translocation assays in the diagnostic work-up of difficult cases. This review is focused on the application of molecular biology techniques in the study of lymphoid tumors. Both conventional and next-generation tests will be addressed, with particular attention to their application to clinical practice.
近年来，DNA 芯片、基因表达谱分析和下一代测序技术阐明了淋巴恶性肿瘤中发生的基因组改变的高度复杂性。这些研究还促成了新的诊断和预后生物标志物的鉴定，这些标志物可能代表新治疗方法的可能靶点。这些最新进展大大扩展了分子检测在常规诊断血液病理学中的应用。因此，可以想象下一代检测将很快在诊断疑难病例时取代传统的克隆性检测和染色体易位检测。这篇综述重点介绍了分子生物学技术在淋巴肿瘤研究中的应用。将讨论传统和下一代检测，特别关注它们在临床实践中的应用。
